Vilon

Vilon is a synthetic dipeptide composed of lysine and glutamic acid (Lys-Glu, KE), developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology in the 1990s. It is the shortest peptide in the Khavinson bioregulator family. Within the Khavinson framework, Vilon is classified as a thymus and immune system bioregulator, proposed to regulate gene expression in thymic and immune tissue. The compound is positioned as the synthetic cytogen analog of Thymalin, the thymus-derived polypeptide extract used in Russian clinical practice. Animal studies from the Khavinson and Anisimov laboratories report restoration of T-cell function in aged animals, normalization of CD4/CD8 ratios, reduced spontaneous tumor incidence, and lifespan extension in mice. Russian clinical observations describe immunomodulatory effects in elderly patients. Western peer-reviewed clinical trials are absent. The compound is sold in Russia as a dietary supplement (BAA), with no FDA, EMA, or MHRA approval. The mechanism (direct dipeptide-DNA interaction) is mechanistically questionable for such a small molecule.

The Khavinson Cytogen Family and Vilon's Place

The Khavinson framework groups the synthetic bioregulators into "cytogens", short peptides representing the active sequences extracted from the original tissue-derived "cytomedins":

• Thymalin → Vilon (Lys-Glu, KE): thymus extract → dipeptide synthetic analog ← this article
• Cortexin → Cortagen (Ala-Glu-Asp-Pro): cortex extract → tetrapeptide
• Epithalamin → Epitalon (Ala-Glu-Asp-Gly, AEDG): pineal extract → tetrapeptide
• Prostatilen → Prostamax (Lys-Glu-Asp-Pro): prostate extract → tetrapeptide

Vilon represents the simplest case in the Khavinson cytogen family. The Thymalin polypeptide preparation is a complex thymus extract used in Russian clinical practice for immune disorders since the 1970s. The Khavinson group claimed to have identified Lys-Glu as the principal active dipeptide responsible for Thymalin's biological effects. Whether a dipeptide can recapitulate the complex effects of a multi-component tissue extract is one of the central methodological questions in the Khavinson framework.

Thymus Biology and Immune Senescence

Vilon's positioning targets thymic involution and age-related immune decline. Thymic involution is the progressive atrophy of the thymus gland with age, beginning around puberty and accelerating after age 40-50. The thymus is the site of T-cell maturation, and its atrophy reduces naive T-cell output in adults. Consequences include reduced T-cell receptor repertoire diversity, shift toward terminally differentiated memory T-cells, reduced response to novel antigens, increased susceptibility to infections in elderly subjects, increased risk of certain cancers, and altered CD4/CD8 ratios.

Evidence-based interventions for immune senescence are limited: vaccination strategies optimized for elderly, IL-7 therapy in trials, sex hormone restoration in selected cases, thymic exosome research, and lifestyle factors. Vilon is positioned in the Khavinson framework as a thymic restoration intervention, though Western evidence for clinically meaningful immune benefit is essentially absent.

Animal Studies on Vilon

Animal research on Vilon, largely from the Khavinson group and the Anisimov laboratory in St. Petersburg, reports immune restoration in aged animals including increased T-cell counts, improved CD4/CD8 ratios, enhanced response to mitogenic stimulation, improved antibody response to vaccination, and increased natural killer cell activity. Lifespan extension in rodents was reported in the Anisimov 2003 Neuroendocrinology Letters paper. Reduced tumor incidence in aged animals and effects on thymic structure preservation have also been documented. The animal data are reasonably consistent within the Khavinson research community. As with other Khavinson peptides, findings have not been independently replicated in Western laboratories using contemporary methodology standards.

The Mechanistic Plausibility Problem

Vilon presents the most severe mechanistic plausibility challenge of any Khavinson peptide because of its short length. For a dipeptide (Vilon), the sequence space is 20² = 400 possible dipeptides. The proposed tissue-specific gene regulation by Lys-Glu specifically (as opposed to other dipeptides) faces a high plausibility bar.

Alternative mechanisms that could potentially explain observed effects include free amino acid effects from rapid gastrointestinal hydrolysis releasing lysine and glutamic acid (lysine has documented effects on immune function, glutamic acid is the precursor for glutathione synthesis), carrier peptide effects through PepT1 intestinal transporters, immunomodulatory receptor effects on cell-surface receptors, and placebo or observational bias in absence of rigorous controlled trials.

Regulatory Status

• FDA: Not approved as a pharmaceutical
• EMA: Not approved
• Russia/CIS: Registered as a dietary supplement (BAA)
• WADA: Not currently on the prohibited list

Vilon's proposed mechanism follows the Khavinson framework of tissue-specific peptide bioregulation, applied to thymic and immune tissue.

Proposed Khavinson Mechanism

The Khavinson group proposes that Vilon acts through direct DNA interaction in thymic and immune cells. The dipeptide is claimed to penetrate the immune cell plasma membrane, cross the nuclear envelope, bind specific regulatory regions of DNA in thymic and immune-related genes through the Lys-Glu sequence, alter chromatin accessibility, and produce tissue-specific selectivity directed by the specific sequence. The mechanism is more questionable for Vilon than for longer Khavinson peptides because the dipeptide sequence space is small and unique DNA binding by such a short peptide is mechanistically unusual.

Alternative Mechanistic Interpretations

Free amino acid effects: lysine and glutamic acid have documented physiological effects. Lysine is involved in immune function, HSV-1 suppression, and collagen synthesis. Glutamic acid is the precursor for glutathione and a key excitatory neurotransmitter.

PepT1 transporter mediated absorption: dipeptides are recognized by intestinal PepT1 transporters and absorbed intact. The intact peptide could potentially reach systemic circulation in small quantities.

Immune receptor effects: some immune-cell-surface receptors bind small peptides. The peptide could engage receptors involved in immune cell activation or differentiation, though specific targets have not been identified.

Indirect effects through gut microbiome: oral dipeptides can affect gut microbiome composition, with downstream immune effects.

Antioxidant chemistry: small peptides containing glutamic acid can participate in cellular redox balance.

Effects in Animal Models

Regardless of the molecular mechanism, animal studies report improved T-cell function in aged animals, increased thymic preservation, improved CD4/CD8 ratios, enhanced NK cell activity, increased antibody response to vaccination, reduced markers of immune senescence, lifespan extension in some rodent studies, and reduced spontaneous tumor incidence. The animal data have face validity for an immunomodulatory compound. Whether the effects translate to clinically meaningful human immune restoration has not been characterized in rigorous trials.

Pharmacokinetics

The pharmacokinetics of Vilon are not well-characterized in humans. Oral absorption proceeds via PepT1 transporters, but intact Vilon levels in plasma have not been measured in published human studies. Plasma half-life is estimated very short (minutes) given rapid peptidase activity. Tissue distribution and claimed thymic uptake have not been independently verified. Metabolism proceeds through rapid breakdown to lysine and glutamic acid. The pharmacokinetic uncertainty is a significant limitation.

Effects in animal studies (Khavinson and Anisimov laboratories):

• Restoration of T-cell function in aged animals
• Normalization of CD4/CD8 ratios in aged mice
• Increased antibody response to vaccination
• Enhanced NK cell activity
• Improved response to mitogenic stimulation
• Lifespan extension in some rodent studies (Anisimov 2003)
• Reduced spontaneous tumor incidence
• Preservation of thymic architecture in aged animals
• Effects on neuroendocrine-immune interactions

Effects reported in Russian clinical observations (uncontrolled):

• Improvements in immune parameters in elderly patients
• Reduced frequency of respiratory infections
• Adjunctive benefits in chronic infectious diseases
• Subjective well-being improvements
• Combination effects with other Khavinson peptides

Effects in Western peer-reviewed clinical trials: none published. No rigorous Western clinical trials of Vilon exist.

Honest evidence framing: Vilon has a body of animal research from the Khavinson and Anisimov groups reporting consistent immunomodulatory and pro-longevity effects in aged rodent models. The proposed mechanism (direct dipeptide-DNA interaction for tissue-specific gene regulation) is mechanistically implausible for such a short peptide and is not accepted in mainstream Western molecular biology. Alternative mechanisms (free amino acid effects, receptor-mediated effects, antioxidant chemistry, gut microbiome effects) could potentially explain observed phenomena but have not been systematically characterized. Western peer-reviewed clinical trials are absent. The compound has been used as a supplement in Russia for several decades without serious safety signals, but rigorous efficacy validation does not exist.

Important note: Vilon has no FDA-approved dosing protocol. The doses described below come from Russian commercial preparations and Khavinson research framework recommendations.

Standard Russian commercial oral preparation:

• 10-20 mg per capsule (varies by manufacturer)
• 1-2 capsules daily
• Course duration: 10-30 days
• Cycle frequency: 2-3 times per year
• Khavinson framework emphasizes cyclical administration

Off-label parenteral protocols (less common, research contexts):

• 1-5 mg subcutaneously per injection
• Cycles of 10-20 injections
• Periodic cycling

Routes: oral is most common Russian preparation. PepT1 transporter-mediated absorption may allow some intact dipeptide absorption. Subcutaneous use occasional off-label. Intramuscular and intranasal less common.

Stacking considerations within the Khavinson framework: often combined with Epitalon for combined pineal-thymus anti-aging effects, with Pinealon for system-wide gerontological protocols, and with Cortexin or Thymalin in some Russian clinical contexts.

Special populations:

• Pregnancy: avoid. No adequate safety data
• Breastfeeding: avoid
• Pediatric: not recommended
• Active autoimmune disease: theoretical caution given immunomodulatory effects
• Hematological malignancies: theoretical caution given thymic targeting
• Solid organ transplant recipients: avoid due to potential immune restoration interfering with immunosuppression

Adverse effects reported in Russian-language literature and clinical observation:

• Generally well-tolerated
• Mild headache (occasional)
• Mild fatigue (occasional)
• Mild gastrointestinal effects (occasional)
• Rare allergic reactions
• No serious adverse events consistently reported

Theoretical concerns (not well-characterized):

• Autoimmune exacerbation: as an immunomodulator, Vilon could theoretically worsen autoimmune conditions through restoration of T-cell function. Clinical evidence is absent
• Transplant rejection: solid organ transplant recipients on immunosuppression could theoretically experience reduced graft tolerance
• Hematological effects: thymic-targeted intervention raises theoretical concerns in patients with hematological malignancies
• Long-term safety in Western populations not independently characterized
• Drug interactions not systematically studied
• Quality control variability is a significant practical concern
• Bioavailability uncertainty: oral bioavailability of intact dipeptide is not well-characterized

Contraindications and cautions: pregnancy and breastfeeding, pediatric use, hypersensitivity to the peptide, active autoimmune flare, solid organ transplant recipients, active hematological malignancy.

Drug interactions: not systematically studied. Theoretical interactions with immunosuppressants (calcineurin inhibitors, mTOR inhibitors, antimetabolites) and checkpoint inhibitor immunotherapy. Combinations with other Khavinson peptides are common in framework practice.

Pregnancy, breastfeeding, pediatric: avoid.

Athletes: Vilon is not currently on the WADA prohibited list (as of 2026). Status could change.

Vilon is part of the Khavinson bioregulator system, sitting at the simpler end of the cytogen family. Its closest companions:

• Thymalin: the parent porcine thymus polypeptide preparation. Used clinically in Russia since the 1970s for immune disorders. Thymalin is the original cytomedin from which Vilon was supposedly derived as the active dipeptide component
• Thymogen: synthetic dipeptide Glu-Trp (analog of another claimed thymic active component). Used in Russian clinical practice. Different sequence than Vilon
• Epitalon: Khavinson pineal tetrapeptide (AEDG). The most-studied Khavinson peptide internationally. Often combined with Vilon in geriatric protocols
• Pinealon: Khavinson brain tripeptide (EDR). Different tissue target but related Khavinson framework

Common combinations within the Khavinson framework:

• Vilon + Epitalon: the classic Khavinson anti-aging combination, targeting thymic-pineal axis. Anisimov 2003 reported synergistic lifespan extension effects in mouse models
• Vilon + Thymalin: dipeptide cytogen plus polypeptide cytomedin in sequential or combined administration
• Vilon + Pinealon: combined thymic and brain effects in elderly patients
• Vilon + Multi-peptide Khavinson regimen: cycles of multiple Khavinson peptides for system-wide effects

Combinations to approach with caution: immunosuppressants (cyclosporine, tacrolimus, mycophenolate, azathioprine), checkpoint inhibitor immunotherapy (pembrolizumab, nivolumab, ipilimumab), active autoimmune flare, solid organ transplant recipients, active hematological malignancy.

The most actionable framing of Vilon in 2026: this is the simplest Khavinson cytogen, a dipeptide (Lys-Glu, KE) positioned as the synthetic analog of the Russian thymic polypeptide preparation Thymalin. Animal data from the Khavinson and Anisimov laboratories report consistent immune restoration and lifespan extension effects in aged rodent models. The proposed mechanism (direct dipeptide-DNA interaction for thymic gene regulation) faces severe mechanistic plausibility challenges given the dipeptide's small size. Alternative explanations include free amino acid effects, receptor-mediated immune modulation, and antioxidant chemistry. Western peer-reviewed clinical trials are absent. For consumers interested in trying Vilon for immune support or general anti-aging, realistic expectations are warranted: no proof of clinically meaningful efficacy by Western standards exists, quality varies by source, and the dipeptide mechanism remains questionable. For the underlying goals of immune support and healthy aging, evidence-based interventions have substantially stronger evidence bases.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.